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Abstract
Background: Control of skeletal muscle mass and force production is a complex physiological process involving
numerous regulatory systems. Agents that increase skeletal muscle cAMP levels have been shown to modulate
skeletal muscle mass and force production. The dopamine 1 receptor and its closely related homolog, the
dopamine 5 receptor, are G-protein coupled receptors that are expressed in skeletal muscle and increase cAMP
levels when activated. Thus we hypothesize that activation of the dopamine 1 and/or 5 receptor will increase
skeletal muscle cAMP levels thereby modulating skeletal muscle mass and force production.
Methods: We treated isolated mouse tibialis anterior (TA) and medial gastrocnemius (MG) muscles in tissue bath
with the selective dopamine 1 receptor and dopamine 5 receptor agonist SKF 81297 to determine if activation of
skeletal muscle dopamine 1 and dopamine 5 receptors will increase cAMP. We dosed wild-type mice, dopamine
1 receptor knockout mice and dopamine 5 receptor knockout mice undergoing casting-induced disuse atrophy
with SKF 81297 to determine if activation of the dopamine 1 and dopamine 5 receptors results in hypertrophy of
non-atrophying skeletal muscle and preservation of atrophying skeletal muscle mass and force production.
Results: In tissue bath, isolated mouse TA and MG muscles responded to SKF 81297 treatment with increased
cAMP levels. Treating wild-type mice with SKF 81297 reduced casting-induced TA and MG muscle mass loss in
addition to increasing the mass of non-atrophying TA and MG muscles. In dopamine 1 receptor knockout mice,
extensor digitorum longus (EDL) and soleus muscle mass and force was not preserved during casting with SKF
81297 treatment, in contrast to significant preservation of casted wild-type mouse EDL and soleus mass and EDL
force with SKF 81297 treatment. Dosing dopamine 5 receptor knockout mice with SKF 81297 did not significantly
preserve EDL and soleus muscle mass and force although wild-type mouse EDL mass and force was significantly
preserved SKF 81297 treatment.
Conclusions: These data demonstrate for the first time that treatment with a dopamine 1/5 receptor agonist
results in (1) significant preservation of EDL, TA, MG and soleus muscle mass and EDL muscle force production
during periods of atrophy and (2) hypertrophy of TA and MG muscle. These effects appear to be mainly mediated
by both the dopamine 1 and dopamine 5 receptors.
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Dopamine has multiple central and peripheral physiolo-
gical effects. In the brain, dopamine controls a multitude
of functions including locomotor activity, cognition,
emotion, positive reinforcement, food intake and endo-
crine regulation. In the periphery, dopamine modulates
cardiovascular activity (both cardiac and vascular func-
tion), catecholamine release, hormone secretion, renal
function and gastrointestinal motility [1]. Dopamine
mediates its action via the 5 known dopamine receptors
(D1-D5). These five receptors can be subdivided into
two general groups, the D1 receptor/D5 receptor group
(D1-like) and the D2 receptor/D3 receptor/D4 receptor
group (D2-like), based on their molecular structures,
pharmacological activities, and physiological functions
[1-5]. The D1-like receptors predominantly signal by
coupling to Gas which leads to the activation of adeny-
lyl cyclase and the formation of cAMP [1,3,6,7]. The
D2-like receptors signal mainly by coupling to Gai,
thereby inhibiting the activity of adenylyl cyclase
[1,3,8,9]. In addition, alternative G protein coupling has
been described for both the D1-like receptor and the
D2-like receptor groups under specific conditions
[10-13]. The dopamine receptors have been cloned from
many species, including humans, with splice variants of
many of the dopamine receptors identified [1,3]. Gene
expression analysis of the dopamine receptors has
demonstrated that the D1-like receptor group is
expressed centrally in many areas of the brain and per-
ipherally in blood vessels, the adrenal gland, skeletal
muscle and the kidneys [1,4,14-17]. The D2-like recep-
tor group is also expressed centrally in many areas of
the brain and peripherally in the pituitary, blood vessels,
the heart, the adrenal gland, and the kidneys [1,4,15,17].
Pharmacologically, agonists and antagonists that func-
tionally differentiate dopamine receptors have been
described and have been useful in matching biological
activity with individual dopamine receptors [1,17,18].
Skeletal muscle is a plastic tissue which readily
changes mass in response to alterations in physiological
demand for work and metabolic need. Loss of skeletal
muscle mass (atrophy) can be initiated by a variety of
stimuli including disuse, nerve damage, glucocorticoid
use, sepsis, cachexia, chronic pulmonary obstructive dis-
ease, congestive heart failure and muscular dystrophy
[19-28]. Several agents have been shown to modulate
skeletal muscle mass including anabolic steroids, growth
hormone, insulin-like growth factor I, corticotrophin
releasing factor 2 receptor agonists, phosphodiesterase 4
inhibitors, vasoactive intestinal peptide 2 receptor ago-
nists and beta 2 adrenergic receptor agonists [29-36].
We have previously demonstrated that modulation of
skeletal muscle cAMP levels by activation of receptors
that are positively coupled to adenylate cyclase and by
inhibition of phosphodiesterases that degrade cAMP
increase skeletal muscle mass under both physiological
and pathological conditions [31-34]. We were therefore
interested in determining if activation of the dopamine
1 and dopamine 5 receptors would increase skeletal
muscle cAMP thereby resulting in increased muscle
mass and force. To do this, we utilized a selective dopa-
mine 1/dopamine 5 receptor agonist (SKF 81297) to
treat wild-type, dopamine 1 receptor knockout and
dopamine 5 receptor knockout mice and measured ske-
letal muscle cAMP levels, skeletal muscle mass and ske-
letal muscle force production.
Methods
SKF81297 and theophylline were purchased from Sigma
Chemical Company (St. Louis, MO). Male C57BL6 mice
weighing approximately 20-30 grams were purchased
from Charles River (Kingston, NY). The dopamine 1
receptor knockout mice and their corresponding wild-
type mice were purchased from Jackson Laboratories
(Bar Harbor, ME). The dopamine 5 receptor knockout
mice and their corresponding wild-type mice were
o b t a i n e df r o mD r .D a v i dS i b l e y( N I H ,B e t h e s d a ,M D )
and bred at Procter & Gamble. Mice were single-housed
and acclimatized to the conditions of the facility for
approximately 1 week before use. Mice had access to lab
chow and water ad libitum and were subjected to stan-
dard conditions of humidity, temperature and a 12 hour
light cycle. All animal studies described in this report
were conducted in compliance with the US Animal
Welfare Act, the rules and regulations of the State of
Ohio Departments of Health, Procter & Gamble’s policy
on research involving animals with strict oversight for
care/welfare and were approved by the Procter & Gam-
ble Institutional Animal Care and Use Committee.
Evaluation of cAMP generation by dopamine 1/5 receptor
agonist treatment of skeletal muscle in tissue bath
Evaluation of muscle cAMP levels was performed as
described by us previously [32,33]. Briefly, skeletal muscle
tissue baths were prepared by dissecting the medial gas-
trocnemius and tibialis anterior muscles from both the
right and left legs of mice and pinning the muscles at
resting length on rubber supports adhered to glass
microscope slides. The muscles were then incubated with
continuous aeration with 95% oxygen/5% carbon dioxide
in 25 ml of a 30°C pH 7.4 Krebs-Ringers solution. After
15 minutes this solution was changed and was replaced
with 25 ml of pH 7.4 Krebs-Ringer solution containing
25 mM theophylline and the muscles were incubated at
30°C with continuous aeration for an additional 15 min-
utes. 25 mM theophylline was added to the incubation
bath in order to inhibit phosphodiesterase mediated
breakdown of cAMP. The test compounds were added to
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theophylline and the muscles were incubated for 1 hour
after which they were removed from the baths, blotted
dry and snap frozen in liquid nitrogen. The muscles were
prepared for cAMP analysis by grinding into a fine pow-
der in liquid nitrogen using a mortar and pestle followed
by dissolving the powdered muscle in lysis buffer and
incubating for 30 minutes as specified by the cAMP kit
manufacturer (Amersham Pharmacia Biotech Inc., Piscat-
away, NJ). cAMP levels were then measured using the
Amersham Pharmacia Biotech cAMP measurement kit
RPN225 essentially as recommended by the manufac-
turer. Each experiment was performed in triplicate. The
data is presented as fold increase over control with 1 fold
being equivalent to background rate.
Leg casting disuse-induced muscle atrophy model
Lower leg casting disuse-induced muscle atrophy was
performed as described previously [32,33]. Briefly, mice
were anesthetized with isoflurane and the lower right
leg was casted from the knee to the toes with heat acti-
vated casting material (Vet Lite, Kruuse Inc., Marslev,
Denmark). The test materials (vehicle or 30 mg/kg SKF
81297) were administered by once daily subcutaneous
injections in the midscapular region. Fourteen days after
casting, animals were euthanized by carbon dioxide
asphyxiation followed by cervical dislocation. The cast
was removed and the lower leg muscles (tibialis anterior,
medial gastrocnemius, extensor digitorum longus and
soleus) were dissected rapidly, cleaned of tendons/con-
nective tissue and weighed.
Muscle functional analysis
Ten days after application of casts, eight mice per treat-
ment group were anesthetized using isoflurane. The
casts were removed and the right legs shaved and the
extensor digitorum longus and soleus muscles exposed.
Silk sutures (5-0) were tied to the proximal and distal
tendons of the EDL and soleus muscles and the muscles
were removed. The muscles were then immediately
placed into a bath with oxygenated Ringer’ss o l u t i o n
(95% O2 and 5% CO2), tied to a force transducer and a
fixed post within the bath and stimulated with single
and trains of electrical pulses (1 Hz and 10-200 Hz,
respectively) in order to assess the muscles ability to
generate force. Upon completion of the force generation
analysis, the muscles were removed from the baths,
blotted dry and weighed.
Statistical analysis
Statistical analysis of the data was performed using an
ANCOVA model with treatment effect and starting
weight as the covariates. Pairwise comparisons for all
end-points were generated using least-square means
(SAS, Cary, North Carolina), adjusted for unequal
sample sizes and starting weight.
Results
cAMP generation following dopamine 1 and dopamine 5
receptor activation in skeletal muscle
In order to evaluate if activation of the dopamine 1 and
dopamine 5 receptors would increase cAMP levels in
skeletal muscle, mouse TA and MG muscles were
removed, incubated in tissue baths, treated with the
dopamine 1 and dopamine 5 receptor selective agonist
SKF 81297 and cAMP levels measured. As can be seen
in Table 1, treatment of TA muscle with SKF 81297 (in
the presence of theophylline which was added to inhibit
phosphodiesterases and prevent the breakdown of
cAMP during the collection period) resulted in a statis-
tically significant (p < 0.05) 1.5 fold increase in cAMP
levels over theophylline alone, while treatment of the
MG muscle with SKF 81297 plus theophylline resulted
in a statistically significant 1.9 fold increase in cAMP
levels over theophylline alone. Thus, treatment of skele-
tal muscle with a dopamine 1 and dopamine 5 receptor
selective agonist increases muscle cAMP levels.
Treatment of mice undergoing disuse induced atrophy
with SKF 81297
SKF 81297 was administered to C57Bl6 mice with their
lower right leg casted (knee to ankle walking cast) in
order to evaluate the effect of activation of the dopamine
1 and dopamine 5 receptors on atrophying (right lower
leg muscle) and non-atrophying (left lower leg muscle)
skeletal muscle mass. As can be seen in Table 2, once
daily treatment of casted mice with 30 mg/kg SKF 81297
for fourteen days resulted in statistically significant (p <
0.05) increase in the mass of the uncasted left leg TA
(+9%) and MG (+7%) muscles when compared to vehicle
control. In addition, treatment with SKF 81297 resulted
in a statistically significant (p < 0.05) reduction in the
casted right leg TA (32%) and MG (49%) atrophy-
induced muscle mass loss compared to vehicle control.
Table 1 Effect of dopamine 1/5 receptor agonist
treatment on skeletal muscle cAMP levels
Treatment Tibialis Anterior
cAMP
levels +/- SEM
(femptomoles/mg)
Medial
Gastrocnemius
cAMP levels +/- SEM
(femptomoles/mg)
Theophylline 329.6 +/- 62.6 286.4 +/-58.8
SKF 81297 +
theophylline
486.6 +/- 81.4* 535.3 +/-53.6*
* - statistically significant (p < 0.05) versus theophylline.
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skeletal muscle mass and force production in wild-type,
dopamine 1 receptor knockout and dopamine 5 receptor
knockout mice undergoing disuse induced atrophy
In order to determine (1) which dopamine receptor is
responsible for the changes in muscle mass observed fol-
lowing SKF 81297 treatment and (2) if both mass and
force production are preserved, we evaluated dopamine 1
receptor and dopamine 5 receptor knockout mice, along
with their genetically matched wild-type control animals,
in the mouse casting-induced atrophy model. Casting
resulted in a statistically significant (p < 0.05) loss of both
w i l d - t y p em o u s eE D Lm u s c l em a s sa n df o r c e( - 2 4 %
mass/-22% force) and dopamine 1 receptor knockout
mouse EDL muscle mass and force (-22% mass/-14%
force). Casting also resulted in a loss of wild-type mouse
soleus muscle mass and force (-34% mass/-29% force)
and dopamine 1 receptor knockout mouse soleus muscle
mass and force (-33% mass/-39% force). (Table 3). Dosing
with SKF 81297 resulted in a statistically significant (p <
0.05) reduction in the casting-induced loss of wild-type
mouse EDL muscle mass and force (+42% mass/+51%
force increase compared to vehicle treated animals) and
soleus muscle mass and force (+23% mass/+25% force
increase compared to vehicle treated animals). In con-
trast, SKF 81297 treatment did not result in a statistically
significant reduction in the casting-induced loss of mus-
cle mass and force in dopamine 1 receptor knockout
mouse EDL muscle mass and force (-5% mass/-19% force
decrease compared to vehicle treated animals) and soleus
muscle mass and force (+9% mass/+2% force increase
compared to vehicle treated animals) (Table 3). There
was a small increase in casted and SKF 81297 treated
wild type mouse body mass compared to uncasted and
Table 2 Effect of dopamine 1/5 receptor agonist SKF 81297 on atrophying (right, casted) and non-atrophying (left,
uncasted) C57Bl6 mouse tibialis anterior and medial gastrocnemius muscle mass
Parameter Treatment Number of mice Mean Standard Error
Initial body mass (grams) Vehicle 1 8 23.4 0.2
SKF 81297 8 23.9 0.2
Final body mass (grams) Vehicle 1 8 23.5 0.2
SKF 81297 8 24.2 0.3
Right Casted Tibialis Anterior (milligrams) Vehicle 1 8 30.9 1.0
SKF 81297 8 33.3* 0.7
Right Casted Medial Gastrocnemius (milligrams) Vehicle 1 8 32.4 1.1
SKF 81297 8 36.3* 0.8
Left Uncasted Tibialis Anterior (milligrams) Vehicle 1 8 38.3 0.7
SKF 81297 8 41.9* 0.7
Left Uncasted Medial Gastrocnemius (milligrams) Vehicle 1 8 40.4 0.7
SKF 81297 8 43.5* 0.5
* - statistically significant (p < 0.05) versus appropriate vehicle control.
Table 3 Effects of once daily 30 mg/kg treatment with the dopamine 1/5 receptor agonist SKF 81297 on atrophying
skeletal muscle mass in wild-type (+/+ D1R) and dopamine 1 receptor homozygous knockout (-/- D1R) mice
Parameter Uncasted
Vehicle
+/+ D1R
Casted
Vehicle
+/+ D1R
Casted
SKF 81297
+/+ D1R
Uncasted
Vehicle
-/- D1R
Casted
Vehicle
-/- D1R
Casted
SKF 81297
-/- D1R
# mice 12 11 10 11 11 11
Initial body
mass (grams)
24.6
(1.0)
24.4
(0.9)
24.1
(1.1)
22.1
(1.1)
22.3
(1.1)
21.6
(0.8)
Final body
mass (grams)
24.9
(1.0)
24.2
(0.8)
25.8#*
(1.2)
23.6
(1.1)
22.6#
(1.1)
23.0#
(0.9)
EDL mass
(milligrams)
9.8
(0.4)
7.4#
(0.4)
8.4#*
(0.5)
9.6
(0.4)
7.5#
(0.5)
7.4#
(0.4)
EDL Po
(milliNewtons)
402.8
(16.0)
315.0#
(15.6)
359.5#*
(22.7)
371.0
(11.0)
317.8#
(22.1)
307.6#
(16.3)
Soleus mass
(milligrams)
7.6
(0.3)
5.0#
(0.3)
5.6#*
(0.4)
6.9
(0.3)
4.6#
(0.3)
4.8#
(0.3)
Soleus Po
(milliNewtons)
209.3
(6.1)
149.0#
(6.8)
164.2#
(12.0)
196.2
(11.3)
119.7#
(7.1)
121.4#
(7.0)
All data given as mean + (SEM). * - statistically significant (p < 0.05) versus casted vehicle; # - statistically significant (p < 0.05) versus uncasted vehicle.
Reichart et al. BMC Musculoskeletal Disorders 2011, 12:27
http://www.biomedcentral.com/1471-2474/12/27
Page 4 of 8casted vehicle treated wild type mice. In addition casted
SKF 81297 and vehicle treated dopamine 1 receptor
knockout mice demonstrated a small decrease in body
mass compared to uncasted vehicle treated dopamine 1
receptor knockout mice (Table 3).
Evaluation of dopamine 5 receptor knockout mice
revealed that casting resulted in a statistically significant (p
< 0.05) muscle mass and force loss in both wild-type
mouse EDL muscle (-32% mass/-32% force) and dopamine
5 receptor knockout mouse EDL muscle (-33% mass/-33%
force). Casting resulted in a similar response in wild-type
mouse soleus muscle (-40% mass/-40% force) and dopa-
mine 5 receptor knockout mouse soleus muscle (-32%
mass/-35% force) (Table 4). Treatment with SKF 81297
resulted in a reduction in the casting-induced loss of wild-
type mouse EDL muscle mass and force (significant +21%
mass/+28% force increase compared to vehicle treated ani-
mals) with no significant preservation of casting-induced
loss of wild-type mouse soleus muscle mass and force
(+3% mass/+11% force increase compared to vehicle trea-
ted animals). Treatment with SKF 81297 resulted in a
small and statistically non-significant preservation of dopa-
mine 5 receptor knockout mouse EDL muscle mass and
force (non-significant +10% mass/+20% force increase
compared to vehicle treated animals) with no preservation
of dopamine 5 receptor knockout mouse soleus muscle
mass and force (non-significant -4% mass/-4% force
increase compared to vehicle treated animals) (Table 4).
There was a small increase in casted and SKF 81297
treated wild type mouse body mass compared to casted
vehicle treated wild type mice with casted vehicle trea-
ted wild type mice having a small decrease in body mass
compared to uncasted vehicle treated wild type mice. In
addition, casted SKF 81297 and vehicle treated dopa-
mine 5 receptor knockout mice demonstrated a small
decrease in body mass compared to uncasted vehicle
treated dopamine 1 receptor knockout mice with casted
SKF 81297 dopamine 5 receptor knockout mice having
a small increase in body mass compared to vehicle trea-
ted dopamine 5 receptor knockout mice (Table 4).
Discussion
In this report we demonstrate for the first time that activa-
tion of the dopamine 1/5 receptors results in increased
skeletal muscle cAMP, increased non-atrophying muscle
mass and reduced atrophy-induced loss of muscle mass
and force production. By using knockout mice to differ-
entiate the effects of activation of the dopamine 1 receptor
from that of the dopamine 5 receptor, we demonstrate
that both the dopamine 1 and dopamine 5 receptors med-
iate the anti-atrophy effects of the dopamine 1/5 receptor
selective agonist SKF 81297. Genetic removal of the dopa-
mine 1 receptor (with maintenance of the dopamine 5
receptor) results in a complete loss of the SKF 81297
mediated EDL mass/force preservation, data consistent
with the idea that the dopamine 1 receptor mediates the
effects of SKF 81297. In contrast, genetic removal of the
dopamine 5 receptor (with maintenance of the dopamine
1 receptor) resulted in a partial loss of SKF 81297
mediated EDL mass/force preservation, data that is incon-
sistent with the prior observation that the dopamine 1
receptor mediates the effects of SKF 81297. Together
these findings indicate that both the dopamine 1 and
dopamine 5 receptors mediate the anti-atrophy effects of
SKF 81297. One potential mechanism to explain the above
observations is that the dopamine 1 and 5 receptors
dimerize such that the dopamine 1/dopamine 5 receptor
heterodimers are the maximally effective combination
while dopamine 1 receptor homodimers are less effective
and dopamine 5 receptor homodimers are ineffective.
Table 4 Effects of daily 30 mg/kg dosing with the dopamine 1/5 receptor agonist SKF 81297 on atrophying skeletal
muscle mass and force in wild-type (+/+ D5R) and dopamine 5 receptor homozygous knockout (-/- D5R) mice
Parameter Uncasted
Vehicle
+/+ D5R
Casted
Vehicle
+/+ D5R
Casted
SKF 81297
+/+ D5R
Uncasted
Vehicle
-/- D5R
Casted
Vehicle
-/- D5R
Casted
SKF 81297
-/- D5R
# mice 12 12 12 12 12 12
Initial body
mass (grams)
23.0
(0.5)
22.7
(0.3)
22.3
(0.6)
22.3
(0.3)
22.5
(0.4)
21.8
(0.4)
Final body
mass (grams)
23.0
(0.4)
21.6#
(0.4)
22.8*
(0.7)
23.1
(0.4)
21.3#
(0.5)
22.4#*
(0.4)
EDL mass
(milligrams)
8.8
(0.2)
6.0#
(0.2)
6.6#*
(0.3)
8.8
(0.2)
5.9#
(0.2)
6.2#
(0.2)
EDL Po
(milliNewtons)
351.3
(10.8)
237.3#
(8.0)
269.7#*
(13.6)
348.4
(10.5)
233.1#
(9.2)
256.0#
(12.1)
Soleus mass
(milligrams)
7.5
(0.2)
4.5#
(0.2)
4.6#
(0.2)
7.4
(0.2)
5.0#
(0.2)
4.9#
(0.2)
Soleus Po
(milliNewtons)
202.2
(8.2)
120.7#
(8.1)
130.0#
(8.5)
204.2
(7.6)
132.8#
(8.4)
129.9#
(7.1)
All data given as mean + (SEM). * - statistically significant (p < 0.05) versus casted vehicle; # - statistically significant (p < 0.05) versus uncasted vehicle.
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the dopamine 1 and dopamine 5 receptors have been
described with heterodimers displaying behaviors not
observed with homodimers in response to SKF 81297 sti-
mulation [37,38]. Additional work will be required to con-
firm this potential mechanism and clearly understand the
effect of potential dopamine 1/5 receptor homodimers and
heterodimers have on receptor signaling in myocytes.
In general, the casting-induced changes in muscle mass
and force were of a similar magnitude in wild-type and
dopamine receptor knockout mice, although several
exceptions were noted including: (1) a larger change in
casting-induced EDL mass loss (-22%) compared to cast-
ing-induced EDL force loss (-14%) in dopamine 1 receptor
knockout mice; (2) a larger change in casting-induced
EDL force loss (-19%) compared to casting-induced EDL
mass loss (-5%) in SKF 81297 treated dopamine 1 receptor
knockout mice; and (3) a larger preservation of EDL mus-
cle force (+20%) compared to EDL muscle mass (+10%) in
SKF 81297 treated dopamine 5 receptor knockout mice.
Interestingly, no relative difference in EDL muscle mass or
force were observed in wild-type mice under any experi-
mental condition and no relative difference in soleus mus-
cle mass or force were observed in wild-type, dopamine 1
receptor knockout mice and dopamine 5 receptor knock-
out mice under any experimental conditions. At present it
is unclear as to the mechanism that leads to the difference
in EDL muscle force versus mass changes in the dopamine
receptor knockout mice, although in another muscle
cAMP modulating receptor system, it has been reported
that short term activation of the beta 2 adrenergic receptor
increases EDL muscle force without increasing muscle
mass in wild-type mice [39]. The greater reductions in
EDL force relative to mass that we observed in dopamine
receptor knockout mice may indicate that the dopamine 1
and dopamine 5 receptors function to modulate skeletal
muscle force in a manner that is dissociated from the
effect these receptors have on modulating skeletal muscle
mass (similar to that observed with the beta 2 adrenergic
receptor), although the effects of the dopamine 1 and
dopamine 5 receptors on muscle force generation appear
to be more complicated than that of the beta 2 adrenergic
receptor mediated effects since we did not observe an
increase in EDL force versus mass in wild-type mice trea-
ted with SKF 81297 (both increased similarly). Further
study will be required to understand the role of the dopa-
mine 1 and dopamine 5 receptors in mediating EDL mus-
cle force.
All of the four lower leg muscles examined (MG, TA,
EDL and soleus) responded to SKF 81297 treatment
with a reduction in atrophy-induced mass loss,
although there was some experiment-to-experiment
variability in the magnitude of the response. In the
experiment in which we examined the effects of SKF
81297 treatment on both casted and non-casted TA
and MG muscles, the magnitude of the reduction in
muscle mass loss in the casted leg muscle (3.2 mg
averaged difference in muscle mass between SKF 81297
and vehicle treated muscles) and the gain in muscle
mass in the uncasted leg muscle (3.4 mg averaged dif-
ference in muscle mass between SKF 81297 and vehicle
treated muscles) was similar. The fact that the absolute
gain in muscle mass was similar in both the SKF 81297
treated casted and uncasted leg muscles indicates that
there was minimal casting induced hypertrophy of the
uncasted leg, with the increase in muscle mass coming
from the effect of SKF 81297 treatment. This is consis-
tent with our previous observations using the lower leg
casting method, in which we did not observe differ-
ences in uncasted lower leg muscle mass when we
compared casted and uncasted animals. The lack of
casting induced hypertrophy of the uncasted leg results
from the fact that the lower leg casts used are relatively
small and do not impede the movement of the mice
since they are walking casts (RJI personal observation).
The observation that different muscles, in different
mice strains and in different physiological states (nor-
mal versus atrophying) respond similarly to SKF 81297
demonstrates a robustness in the dopamine 1/5 recep-
tor response.
Previous reports have demonstrated several major
roles for dopamine receptors in skeletal muscle. The
first involves modulation of glycogen concentration, gly-
cogen synthase activity and insulin-stimulated glucose
transport in skeletal muscle [40]. These effects are
mediated by elevated muscle cAMP levels and are the
result of a direct effect of levodopa action on skeletal
muscle since the effects are observed in isolated muscle
in tissue bath [40]. A second reported effect of dopa-
mine on skeletal muscle is an improvement in dia-
phragm muscle force development and a reduction in
diaphragm apoptosis in vitro [41]. Finally, dopamine has
been reported to reduce diaphragm fatigue in vivo by
increasing diaphragm muscle blood flow [42]. Together
these results demonstrate that dopamine has multiple
roles in skeletal muscle including modulating energy
storage, modulating muscle force production and con-
trolling muscle fatigue. While the observation that dopa-
mine 1/5 receptors are expressed in skeletal muscle
suggest that these effects may be mediated by the dopa-
mine 1/5 receptors, the use of the non-selective dopa-
mine receptor agonists (dopamine, levodopa and l-dopa)
makes these conclusions somewhat tentative for the fol-
lowing reasons. First, it has been demonstrated that in
skeletal muscle cells, dopamine (a metabolite of levo-
dopa) can activate the beta 2 adrenergic receptor and
the effects of dopamine can be blocked with a beta
2 adrenergic receptor antagonist but not a dopamine
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antagonist [43,44]. Thus, the effects of dopamine on
skeletal muscle that have been previously described may
actually be the result of activation of the beta 2 adrener-
gic receptor and not the result of direct dopamine
receptor activation. In support of this, Smith et al. [40]
demonstrate that the effects of levodopa on glycogen
storage could be reversed by using a beta 2 adrenergic
receptor antagonist. In addition, Pierce et al. [41] argue
that the effects of dopamine on muscle performance
may be mediated via the beta 2 adrenergic receptor. In
contrast to these previous studies, our studies were per-
formed with a very selective dopamine 1/dopamine 5
receptor agonist that is devoid of beta 2 adrenergic
receptor affinity [45]. In addition, we demonstrate that
the increase in muscle mass and force production
observed with the selective dopamine 1/dopamine 5
receptor agonist could be abrogated when the dopamine
1 receptor and to a lesser extent the dopamine 5 recep-
tors are genetically deleted. Together, our data argues
that the skeletal muscle effects we observed including
the increase in mass and force production are the result
of direct stimulation of the dopamine 1 and the dopa-
mine 5 receptors and do not result from off-target acti-
vation of the beta 2 adrenergic receptor. Thus, this
report demonstrates for the first time that activation of
the dopamine 1 and dopamine 5 receptors results in
increased cAMP production and increased muscle mass
and force production. Additional studies using selective
dopamine receptor agonists and mice lacking specific
dopamine receptors will be required before we under-
stand if the effects of dopamine on skeletal muscle gly-
cogen utilization, insulin resistance, fatigue and force
output are mediated by the dopamine 1 and the dopa-
mine 5 receptors.
Conclusion
We demonstrate for the first time that activation of the
dopamine 1 receptor and to a lesser extend the dopa-
mine 5 receptor results in modulation of skeletal muscle
mass and force under both atrophying and non-atrophy-
ing conditions.
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